<DOC>
	<DOCNO>NCT00089492</DOCNO>
	<brief_summary>This study ass safety efficacy once-daily administration Fuzeon compare twice-daily administration HIV-1 infect patient receive prior treatment . Patients also receive optimize treatment consist antiretroviral ( ARV ) therapy determine treat physician . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety Once-Daily Fuzeon ( Enfuvirtide ) Dosing Versus Currently Recommended Twice-Daily Dosing Human Immunodeficiency Virus-Type 1 ( HIV-1 ) Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>HIV1 infect adult adolescent &gt; =16 year age ; HIV1 RNA &gt; =5000 copies/mL ; prior experience document resistance 3 currently available class ARV drug ( nucleoside reverse transcriptase inhibitor , nonnucleoside reverse transcriptase inhibitor , protease inhibitor ) . history prior use Fuzeon T1249 ; female patient pregnant breastfeeding , plan become pregnant study ; current severe illness ; currently take drug affect immune system , HIV vaccine , investigational agent condition HIV/AIDS .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>